Study of Pembrolizumab Versus Docetaxel in Participants Previously Treated for Non-Small Cell Lung Cancer (MK-3475-033/KEYNOTE-033)

NCT02864394 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

425

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

BIOLOGICAL: Pembrolizumab
DRUG: Docetaxel

Sponsor

Merck Sharp & Dohme LLC